CODX Stock News: Robbins LLP is Investigating Co-Diagnostics, Inc. (CODX) on Behalf of Shareholders

Author's Avatar
Aug 24, 2022

Shareholder rights law firm Robbins+LLP is investigating Co-Diagnostics, Inc. (NASDAQ: CODX) and its officers and directors to determine whether they breached fiduciary duties and violated securities laws by misleading investors regarding demand for the Company's Logix Smartâ„¢ COVID-19 Test. Co-Dx purports to develop, manufacture, and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural application.